Archives

Perfusfind S.L.

Abstract The use of temporary mechanical circulatory support (tMCS) in cardiogenic shock patients has increased during the last decades with most management strategies relying on observational studies and expert opinion,..

Perfusfind S.L.

Abstract Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is used in case of potentially reversible cardiac failure and restores systemic hemodynamics. However, whether this is followed by improvement of microcirculatory perfusion is..

Perfusfind S.L.

Abstract Introduction Spinal cord infarction (SCI) or ischemia is a rare but devastating complication of venoarterial extracorporeal membrane oxygenation (VA ECMO). The natural course and outcomes are poorly studied. Methods..

Perfusfind S.L.

Abstract Background While left ventricular (LV) venting reduces LV distension in cardiogenic shock patients on venoarterial extracorporeal membrane oxygenation (VA-ECMO), it may also amplify risk of acute brain injury (ABI). We..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is a highly complex clinical condition that requires a management strategy focused on early resolution of the underlying cause and the provision of circulatory support. In..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation is increasingly being used to support patients with hypoxemic respiratory failure and cardiogenic shock. During the COVID-19 pandemic, consensus guidance recommended extracorporeal life support for patients..

Perfusfind S.L.

Abstract Background The use of Extracorporeal Membrane Oxygenation (ECMO) remains associated with high rates of complications, weaning failure and mortality which can be partly explained by a knowledge gap on..

Perfusfind S.L.

Abstract Introduction The mobilization and ambulation of patients with severe cardiogenic shock supported with peripheral veno-arterial extracorporeal membrane oxygenation (pVA-ECMO) and concomitant femoral intra-aortic balloon pump (IABP) support is not..

Perfusfind S.L.

Abstract Objective: Impella 5.5 (Abiomed, Danvers, MA, USA) is a temporary mechanical circulatory support device used for patients in cardiogenic shock. This review provides a comprehensive overview of the device’s..

Perfusfind S.L.

Abstract Cardiogenic shock (CS) is one of the most challenging areas in cardiology, where hard evidence is often limited. Several factors contribute to this scarcity. Patients with CS are typically..

Perfusfind S.L.

Abstract Summary Cardiogenic shock is a complex syndrome defined by systemic hypoperfusion and inadequate cardiac output arising from a wide array of underlying causes. Although the understanding of cardiogenic shock..

Perfusfind S.L.

Abstract Background: Hydroxocobalamin increases systemic blood pressure through nitric oxide pathway suppression. However, its effects on hypotension during extracorporeal membrane oxygenation (ECMO) are unknown. The objective of this study was to..

Perfusfind S.L.

Abstract Background: Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used for refractory cardiogenic shock (CS). Although guidelines have downgraded the recommendations for intra-aortic balloon pump (IABP) in CS, escalation from..

Perfusfind S.L.

Abstract In recent decades, the use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has increased. In acute cardiogenic shock, VA-ECMO implantation can serve as a bridging solution to facilitate recovery, provide..

Perfusfind S.L.

Abstract Cardiogenic shock is a critical condition that affects up to 10% of patients hospitalized with acute myocardial infarction (AMI), representing the primary cause of death in this group [, ]...

Perfusfind S.L.

Abstract Background: Veno-Arterial Extracorporeal membrane oxygenation (VA-ECMO) provides temporary cardiopulmonary support in the setting of refractory cardiogenic shock. Mechanical ventilation and sedation often accompanies VA-ECMO support and carry the increased risk..

Perfusfind S.L.

Abstract Introduction This study aimed to investigate the relationship between acquired antithrombin deficiency in patients undergoing postcardiotomy extracorporeal membrane oxygenation (PC-ECMO) and thromboembolic or haemorrhagic events such as bleeding, peripheral..

Perfusfind S.L.

Abstract Endothelial injury is usually considered as a major com-ponent of the systemic inflammatory response observed during veno-arterial extracorporeal membrane oxygena-tion (VA-ECMO) support. Yet, few data are avail-able to support..

Perfusfind S.L.

Abstract Background: Left atrial veno-arterial extracorporeal membrane oxygenation (LAVA-ECMO) is a novel mechanical cardiocirculatory support strategy that provides robust cardiocirculatory support and simultaneous left and right atrial venting via a multi-fenestrated..

Perfusfind S.L.

Abstract Background Central venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a commonly employed strategy to support patients in refractory postcardiotomy cardiogenic shock (RPCS). This support can be provided using either indirect..

Perfusfind S.L.

Abstract Background Evidence supporting  with unfractionated heparin (UFH) in patients with an intra-aortic balloon pump (IABP) to prevent  remains limited, while bleeding risks remain high. Monitoring heparin in this setting with anti-factor..

Perfusfind S.L.

Abstract Purpose: Patients receiving venoarterial extracorporeal membrane oxygenation (VA‑ECMO) frequently develop arte‑rial hyperoxaemia, which may be harmful. However, lower oxygen saturation targets may also lead to harmful episodes of hypoxaemia...

Perfusfind S.L.

Abstract Endothelial injury is usually considered as a major com-ponent of the systemic inflammatory response observed during veno-arterial extracorporeal membrane oxygena-tion (VA-ECMO) support [1, 2]. Yet, few data are avail-able..

Perfusfind S.L.

Abstract Extracorporeal life support (ECLS) therapy is increasingly being used to support children with refractory cardiorespiratory failure, but its use is occasionally associated with complications. Neonatal aortic dissection in association..

Perfusfind S.L.

Abstract The management of cardiogenic shock is an ongoing challenge. Despite all efforts and tremendous use of resources, mortality remains high. Whilst reversing the underlying cause, restoring/maintaining organ perfusion and..

Perfusfind S.L.

Abstract Purpose of Review To present an abridged overview of the literature and pathophysiological background of adjunct interventional left ventricular unloading strategies during veno-arterial extracorporeal membrane oxygenation (V-A ECMO). From..

Perfusfind S.L.

Abstract Aims Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a life-saving procedure for supporting patients with cardiogenic shock after cardiac surgery. This work aimed to analyse the impact of changes in..

Perfusfind S.L.

Introduction: Picture this: You're standing at the bedside of a critically ill patient in the ICU, their life hanging by a thread as cardiogenic shock takes hold. The monitors are..

Perfusfind S.L.

Abstract Despite advances in therapy, the incidence of cardiogenic shock continues to increase, with significant mortality that has improved minimally over time. Treatment options for cardiogenic shock are complex and..

Perfusfind S.L.

Abstract Heart failure (HF) is a frequent and severe condition. It is estimated that one in four patients will die within a year following hospitalization for acute decompensation, with significant..